288 related articles for article (PubMed ID: 10881028)
1. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
2. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
[TBL] [Abstract][Full Text] [Related]
3. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
4. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
5. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
[TBL] [Abstract][Full Text] [Related]
6. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity.
Kumakura Y; Vernaleken I; Gründer G; Bartenstein P; Gjedde A; Cumming P
J Cereb Blood Flow Metab; 2005 Jul; 25(7):807-19. PubMed ID: 15729292
[TBL] [Abstract][Full Text] [Related]
7. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDOPA kinetics in brain tumors.
Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
[TBL] [Abstract][Full Text] [Related]
9. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
[TBL] [Abstract][Full Text] [Related]
10. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
Hoshi H; Kuwabara H; Léger G; Cumming P; Guttman M; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):57-69. PubMed ID: 8417011
[TBL] [Abstract][Full Text] [Related]
11. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.
Kumakura Y; Cumming P
Neuroscientist; 2009 Dec; 15(6):635-50. PubMed ID: 19793723
[TBL] [Abstract][Full Text] [Related]
12. Extrastriatal mean regional uptake of fluorine-18-FDOPA in the normal aged brain--an approach using MRI-aided spatial normalization.
Nagano AS; Ito K; Kato T; Arahata Y; Kachi T; Hatano K; Kawasumi Y; Nakamura A; Yamada T; Abe Y; Ishigaki T
Neuroimage; 2000 Jun; 11(6 Pt 1):760-6. PubMed ID: 10860800
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
14. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
[TBL] [Abstract][Full Text] [Related]
15. Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease.
Kumakura Y; Danielsen EH; Gjedde A; Vernaleken I; Buchholz HG; Heinz A; Gründer G; Bartenstein P; Cumming P
Neuroimage; 2010 Feb; 49(4):2933-9. PubMed ID: 19941962
[TBL] [Abstract][Full Text] [Related]
16. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
[TBL] [Abstract][Full Text] [Related]
17. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
18. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
[TBL] [Abstract][Full Text] [Related]
19. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
Nurmi E; Ruottinen HM; Bergman J; Haaparanta M; Solin O; Sonninen P; Rinne JO
Mov Disord; 2001 Jul; 16(4):608-15. PubMed ID: 11481683
[TBL] [Abstract][Full Text] [Related]
20. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.
Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K
Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
